Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.

摘要: BACKGROUND: Indolent nonfollicular non-Hodgkin B-cell lymphomas (INFLs) are clonal mature proliferations for which treatment has not been defined to date. METHODS: In this phase 2 study of patients with advanced INFL, the authors evaluated efficacy and safety first-line rituximab, fludarabine, cyclophosphamide (FCR) as induction immunochemotherapy (rituximab 375 mg/m2 intravenously on day 1 each cycle days 14 cycles 4 5; fludarabine 25 2-4, 250 Days 2-4) every 28 6 followed by a maintenance infusions rituximab (375 1) months responders. RESULTS: Forty-seven were enrolled. Among 46 evaluable (28 men; median age, 59 years), 19 diagnosed lymphoplasmacytic lymphoma, 21 small lymphocytic nodal marginal zone lymphoma. The overall response rate after was 89.1% 67.4% complete remission (CR) (CR/unconfirmed CR) 21.7% partial rate. After follow-up 40.9 months, failure-free survival progression-free rates both 90.1%, 97.4%. main toxicity hematologic, related grade 3 neutropenia observed in 55.3% patients. CONCLUSIONS: FCR therapy short is highly effective regimen acceptable toxicity. Cancer 2012. © 2011 American Society.